Phase 3 Malaria Vaccine Trial Effective: AGEN, GSK
A promising new malaria vaccine from GlaxoSmithKline (GSK $43.72) offers hope to children in Africa.The final stage trial cut the risk of clinical malaria by 56 % and severe malaria by 47%. Malaria killed 781,000 people in 2009 and is a big problem in sub-Sahara Africa. The data was presented...
Another Big Rally on Europe Non-News: Biotech Sector Lagging
Another stealth rally led by financials took the S&P 500 up 2% helped by a turbo boost in the last 90 minutes as The Guardian reported that France and Germany agreed to boost the rescue fund.Oil prices rebounded driving energy shares higher. Some pundits as well as EU officials were...
Collateral Damage from Illumina (ILMN) Warning: Looking For New Buys
11/21/11 The diagnostics and tools sector remain weak trading down about 1.9% slightly better than NASDAQ down 2.5%. Within the life sciences we prefer biopharmaceutical stocks because of M&A potential and less sensitivity to earnings. From October 11,2011 Despite a nice rally yesterday we...
Investor Uprising – Guide to Biotech Investing
There is an excellent Guide to Biotech Investing on the Investor Uprising blog. You will need a IU account to view the document http://www.investoruprising.com/document.asp?doc_id=206689...
Innovations Continue to Drive Market Gains
Over $50B in Product Sales Have Been Posted in the Last 20 Years as a Result of Biotech Advances Biotechnology stocks were up about 12% over the past 12 months through February 2011, underperforming the Nasdaq, which was up 29%. The NYSE Arca Biotech ETF did better, up 23%. Since the recent...